Previous 10 | Next 10 |
Orchard Therapeutics (ORTX) trades 10.5% high in premarket trade after executing a securities purchase agreement to raise gross proceeds of $150M through the sale of 24.1M shares in a PIPE financing at $6.22/share.Proceeds to be used for supporting its growing commercial capabilitie...
BOSTON and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise gross proceeds of $150 million resulting from the sale of 24,115,755 shares through a private...
Orchard Therapeutics (ORTX) announces the appointment of healthcare and biotech industry veteran Braden Parker as its Chief Commercial Officer.Parker has 20 years of experience in the field and previously held positions at Celgene and PTC Therapeutics. He joined Orchard from PT...
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of com...
Nine abstracts accepted demonstrating potential of HSC gene therapy to treat multiple neurodegenerative disorders New clinical data from all eight patients treated with OTL-203 for Mucopolysaccharidosis type I (MPS I) Biomarker data from first three patients treated with...
BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and ...
The FDA has granted Orchard Therapeutics' (ORTX) OTL-200 its Regenerative Medicine Advanced Therapy ((RMAT)) designation for the treatment of early-onset metachromatic leukodystrophy ((MLD)), a rare hereditary disorder characterised by accumulation of fats called sulfatides.The agen...
BOSTON and LONDON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200, an investigational ex ...
Citing the impact of the COVID-19 pandemic on certain development activities, Orchard Therapeutics ([[ORTX]] -3.9%) now expects to file US marketing application for OTL-103 in Wiskott-Aldrich Syndrome ((WAS)), in 2022.The company said that delayed activities is impacting the ti...
Preparations on Track for First Half 2021 Commercial Launch of Libmeldy™ (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU Filing Strategy for OTL-200 Biologics License Application (BLA) in MLD in the U.S. to be Communicated by Mid-202...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....